Genes Involved in Therapeutic Response: K. D. Tew, discussion leader
B. R. Franza, "Disease Specific Targets for Therapy."
A. B. Pardee, "Finding New Genes by Differential Display."
A. Gudkov, "Identification of Drug Sensitivity Genes Using Genetic
Suppressor Elements."
Dynamic Structure Evaluation using Multi-Dimensional NMR: R. C.
Jackson, discussion leader.
J. Cavanagh, "Introduction to Multi-Dimensional NMR Analysis of a Mr-
14 K Globular Protein, SPoOF."
The Nucleus: Structural Aspects in Apoptosis: J. A. Hickman, discussion
leader
P. Cook, "Transcription and Replication Factories."
Y. Lazebnik, "Nuclear Changes in Apoptosis in Vitro."
S. Kaufmann, "Changes in Nuclear Proteins During Drug-and Hormone-
induced Apoptosis."
Novel Genes in Drug Resistance: W. T. Beck, discussion leader
S. P. C. Cole, "The Role of MRP in Drug Resistance."
I. Roninson, "Cisplatin Sensitivity Genes."
Gene Targeted Therapy: L. C. Erickson, discussion leader
K. J. Scanlon, "Utility of Anti-Oncogen Ribozymes in Human Cancer."
P. M. Potter, "Ribozyme-Mediated Modulation of Tumor Specific
Transcripts."
M. Dietel, "Anti-Sense Ribozymes to Modify Cytostatic."
M. Litwack and T. Tritton, discussions leaders
M. Litwack, P. Perkins, M. Wolpert, "Round Table Discussion: Surviving
the Funding Crisis in the 90's."
T. Tritton, "Poster Discussion Session."
Preclinical and Clinical Strategies for the Reversal of Drug Resistance:
A. E. Pegg, discussion leader
A. F. List, "Reversal of Multi-Drug Resistance."
J. R. Bertino, "Reversal of Antimetabolite Resistance."
A. E. Pegg, "Reversal of Chloroethlating Agent Resistance."
Difference as a Cancer Chemotherapeutic Modulity: G. P. Studzinski,
discussion leader
M. B. Sporn, "Interaction of Low Molecular Weight Ligands with the
TGF Beta Regulatory System."
E. Dmitrovsky, "Retinoic Acid, its Rearranged Receptor, and Acute
Promyelocytic Leukemia."
Cell Cycle Control: J. A. Houghton, discussion leader
P. M. O'Connor, "Cell Cycle Control and Chemo-Sensitivity in Tumor
Cells."
S. Lowe, "p53 Modulates the Cellular Response to Oncogenes and Anti-
Cancer Agents."
A. Koff, "Stopping the Cell Cycle: p27 Prevents Activation of CDK2."
|